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Abstract-EG626
(oxagrelate), a specific inhibitor of cyclic AMP phosphodiesterase, produced in vitro a concentration-dependent inhibition of platelet aggregation induced by collagen and ADP in human platelets.
When adenosine was added to the platelet rich plasma (PRP) in the presence of a threshold concentration of EG626, the potency of adenosine in inhibiting platelet aggregation was markedly potentiated.
This potentiating effect of EG626 proved to be synergistic, but not additive and was accompanied by a marked accumulation of cyclic AMP in the platelets.
The antiaggregating and cyclic AMP increasing activities of adenosine were little affected by S-(p-nitrobenzyl)-6-thioguanosine (6TG) , an uptake in hibitor of adenosine, or 2'-deoxycoformycin, an inhibitor of adenosine deaminase. The incorporation of adenosine into platelets was abolished by 6TG. These observations indicate that incorporation of adenosine into platelets is not required for inhibition of aggregation or an increase in cyclic AMP and that the site of action of adenosine is probably extracellular.
It also appears that the synergistic action by EG626 is not the result of an inhibition of adenosine uptake and/or adenosine deaminase.
This speculation is supported in part by the finding that EG626 also potentiates the antiaggregating activity of 2-chloroadenosine. Antiaggregating activity of prostaglandin E,, an activator of adenylate cyclase, was markedly poten tiated in combination with EG626.
Dibutyryl cyclic AM P showed a time-dependent inhibition of the platelet aggregation, and the inhibitory action was markedly potentiated by EG626. Qualitatively similar results were obtained with another phosphodiesterase inhibitor, 3-isobutyl-1 -methylxanthine (IBMX). All these data suggest that the synergistic potentiation of the antiaggregating activity of adenosine by EG626 might be due to the synergistic accumulation of cyclic AM P in the platelets. This action is mediated through activation of adenylate cyclase by adenosine in combination with the inhibition of cyclic AMP phosphodiesterase by EG626.
7-Ethoxycarbonyl-4-hydroxymethyl-6,8 dimethyl-1 (2H)-phthalazinone (EG626, ox agrelate) was synthesized by Ishikawa et al. (1) in our laboratory for the purpose of studying antiatherosclerotic agents. This compound has potent inhibitory activity on cyclic AMP phosphodiesterase (2, 3) and inhibits platelet aggregation (4, 5) . In addition, it prevents edematous changes in the rabbit aorta induced by angiotensin II and cholesterol (2, 6). In the course of investigating the pharmacological properties of EG626, we found that this agent markedly potentiated the antiaggregating activity of adenosine in human platelets in vitro.
Adenosine and closely related compounds are potent inhibitors of platelet aggregation (7-9). The mechanism responsible for this inhibition has been the subject of con siderable controversy. Adenosine reportedly inhibits platelet aggregation apparently by acting on the extracellular membrane receptor to increase levels of platelet adenosine 3':5' cyclic monophosphate (cyclic AMP) through activation of adenylate cyclase (10). On the other hand, with inhibitors of adenosine transport such as papaverine or pyrimidopyrimidines, which also inhibit platelet cyclic AMP phosphodiesterase and potentiate the inhibition of aggregation by adenosine (11), no definite conclusion was reached.
We investigated the potentiation of the antiaggregating activity of adenosine by EG626 with respect to adenosine transport and cyclic AMP levels in platelets. Since EG626, 6TG and PGE1 were hardly soluble in aqueous solution, they were dissolved in dimethylsulfoxide (DMSO , Art. 2950, Merck), which was present in a final concentration of 0.5% or less in all experi ments with these agents, and this concen tration had no effect on any of the parameters studied. Aggregating agents such as collagen and ADP were prepared as follows: Collagen was diluted further with SKF Horm buffer to the desired concentration immediately before use, and ADP was dissolved in saline at a concentration of 10-4 M and kept frozen until use. Adenosine, 2-chloroadenosine, dibutyryl cyclic AMP and IBMX were dis solved in distilled water immediately before use.
Materials and Methods

Materials
Platelet aggregation study: Human blood samples were obtained from healthy male volunteers who had not taken any drug or alcohol for at least 2 weeks. Blood was collected into 1/10 volume of 3.8% sodium citrate. Platelet rich plasma (PRP) was prepared by centrifugation at 225 x g for 10 min at room temperature, and platelet poor plasma (PPP) was obtained by further centrifugation of blood at 1670xg for 1 5 min. Platelet aggregation was studied by the turbidometric method of Born (12) , utilizing a dual sample aggregation meter (SiencoTM DP-247E) which was modified to provide continuous stirring and maintenance of con stant temperature (37'C). The standard reaction mixtures consisted of 270 ,al of citrated PRP, 1.5 ,ul of test compound or vehicle, 1.5 PI of adenosine (2-chloro adenosine) or vehicle and 30 ,ul of aggregating agents.
The extent of aggregation was evaluated by the maximum change of light transmission expressed as a percentage, taking the differ ence between light transmission for PRP and PPP as a value of 100%. Percentage of inhibition of aggregation by the test agent was calculated by dividing the percentage of aggregation by that observed in the control run, then multiplying by 100. All individual tests were carried out in rapid succession (within 3 hr of preparation) to avoid potential errors which may occur by altering the sensitivity of the platelets towards aggregating agents during storage at room temperature. The number of platelets was determined with the aid of a Coulter Counter (Coulter Electronics, Inc., Florida, U.S.A).
Determination of cyclic AMP in platelets: Each incubation tube contained 270 A of gel-filtrated platelet (GFP) Suspension (1 2x109 platelets/ml), 1.5 , l of test compound or vehicle, 1.5 ,el of adenosine or vehicle and 30 ,ul of collagen. At the end of incubation for 3 min at 30°C, 1 ml of ice-cold trichloro acetic acid (TCA, 20% w/v) was quickly added. The platelets were then sonicated at 4°C for 30 sec with a sonicator (Ultrasonic Cell Disruptor, model W-225R, Heat System Ultrasonic Inc.). After centrifugation at 300xg for 30 min, the cyclic AMP in the supernatant was succinylated quantitatively and was then measured by a sensitive radio immunoassay procedure (13) using com mercially available kits (Yamasa Shoyu Co., Choshi City, Japan). All assays were per formed in duplicate. GFP were prepared by a modification of the method of Tangen et al. (14) , using Sepharose 2-B and were sus pended in HEPES buffer. HEPES buffer contained a final concentration of: 140 mM NaCI, 2.7 mM KCI, 1 MM MgC12-6H20, 0.1% dextrose, 0.35% bovine serum albumin, 3.75 mM NaH2PO4 and 5 mM HEPES (pH 7. Unlabeled adenosine was included to a final concen tration of 1, 3 and 10 uM. Incubations were carried out at 37 °C for 10 min and terminated by centrifugation at 12,000 x g for 1 min. The supernatant plasma was rapidly removed, and 50 ul was counted for 14C and 3H. The platelet pellet was disrupted by sonication in 500 ul of distilled water and was then transferred quantitatively to liquid scintil lation vials for counting.
The 14C in the platelet pellets was corrected for extracellular 14C on the basis of the [3H] inulin present and the 14C/3H ratio in the plasma. The incorporation of adenosine was calculated in terms of nanomoles per 109 platelets, allowing for variations in its specific activity. All assays were performed in duplicate.
Results shown in the text, (30-300 uM) produced a concentration dependent in hibition of the platelet aggregation induced by 3 ;ug/ml collagen and 1 uM ADP in human platelets in vitro. At a lower concentration of 10 ,iM, the agent had no effect. The 50% inhibition concentrations (IC50) of EG626, which were obtained from a regression curve, were 139.8 uM (n=8) and 170.5 uM (n=8) for collagen and ADP-induced ag gregation, respectively.
Adenosine at concentrations of 3 to 100 uM inhibited the collagen and ADP induced aggregation in a concentration dependent manner, but not with 1 uM or less. When 1, 3 or 10 uM of adenosine was added to PRP in the presence of a threshold concentration (10 uM) of EG626, the potency of adenosine in inhibiting platelet aggregation induced by 3 gig/ml of collagen was markedly potentiated (Fig. 2) . closer to the two axes, as can be seen in Fig. 3 . Thus, the mode of potentiating action seemed to be synergistic and not additive. to the inhibition of adenosine uptake and adenosine deaminase: To determine whether or not the potentiation of antiaggregating activity of adenosine by EG626 is due to the inhibition of adenosine uptake and/or adenosine deaminase, the following experi ments were done. Collagen-induced ag gregation was unaffected by 10 PM 6TG, an uptake inhibitor of adenosine, or by a relatively high concentration of 10 W 2'DCF, an inhibitor of adenosine deaminase, concentrations at which these compounds have been reported to inhibit adenosine uptake (10) and adenosine deaminase (16) .
[8-14C] Adenosine was incorporated into platelets depending on the concentrations (1, 3 and 10 i€M) of adenosine.
In the presence of 10 W 6TG, incorporation of adenosine into platelets was significantly inhibited by approx. 96% or more (Fig. 4) .
Antiaggregating activity of adenosine (1, 3 and 10 PM) was unchanged in the presence of 10 /LM 6TG or 10 W 2'DCF (Fig. 5) . In addition, the enhancing effect of adenosine on cyclic AMP in the platelets was un changed, with or without 6TG or 2'DCF (Fig. 6) . It is well established that 2-chloro adenosine mimics adenosine action, but is not a substrate for uptake (17, 18) and adenosine deaminase (19) . Therefore, the effect of EG626 on the antiaggregating activity of 2-chloroadenosine was examined. 2-Chloroadenosine in concentrations of 0.3 to 3 W (but not 0.1 PM) produced a con centration-dependent inhibition of the collagen-induced platelet aggregation. As shown in Fig. 7 , a threshold concentration (10 /c M) of EG626 markedly potentiated the antiaggregating activity of 2-chloroadenosine. The potentiation was representative in the case of a threshold concentration of 2 chloroadenosine.
3. Analysis of the potentiation of anti aggregating activity of adenosine in relation to the activation of adenylate cyclase by •: 6TG or 2'DCF absent, 10 uM 6TG or 10 pM 2'DCF present, X: 10 pM 6TG or 10 pM 2'DCF alone. Each point represents the mean of 5 separate observations, and vertical bars show S.E. Aggregation of human platelets was induced by addition of 3 ug/ml collagen in vitro. To examine the first criterion, IBMX was used as a phosphodiesterase inhibitor (21, 22) . IBMX in concentrations of 30 to 300 /cM (but not 10 /WM) produced a concentration dependent inhibition of the platelet aggre gation induced by 3 /cg/ml of collagen. The IC50 value obtained from regression curves was 134.8 /tM (n=5), as compared to 139.8 /eM for EG626. EG626 and IBMX exerted nearly an equipotent inhibitory activity on collagen -induced aggregation. When adenosine (1, 3 and 10 /WM) was added to PRP in the presence of a threshold concentration of IBMX (10 and 30 /N), the potency of adenosine in inhibiting platelet aggregation induced by collagen was markedly potentiated, as shown in Fig. 8 . There are reports (23) (24) (25) indicating that PGE, stimulates adenylate cyclase in platelets and produces an inhibitory action on platelet aggregation, accompanied by an elevation of cyclic AMP. Representative superimposed tracings of the combined effect of PGE, with EG626 or IBMX are illustrated in Fig. 9 . The minimum effective concentration of PGE, for inhibiting platelet aggregation varied with the individual and ranged from 10-8 to 10-6 M. When a threshold concentration of PG E, was used in combination with a threshold concen tration of EG626 or IBMX, the potency of PGE, in inhibiting aggregation was markedly potentiated. Investigating the third criterion, dibutyryl cyclic AMP was used as substitute for cyclic AMP since the cell membrane is relatively impermeable to cyclic nucleotides (24) . Dibutyryl cyclic AMP exhibited a greater activity than cyclic AMP, per se, probably reflecting its more lipophilic character. Relatively high concentrations of dibutyryl cyclic AMP were necessary to inhibit the collagen-induced aggregation. The inhibitory action was time-dependent as shown in Fig. 10 , that is, the nucleotide did not exhibit any effect in the case of the 1 min-pre incubation, but markedly inhibited the aggre gation when PRP was preincubated for 20 min in the presence of 200 /€M dibutyryl cyclic AMP. In addition, the potency of dibutyryl cyclic AMP in inhibiting platelet aggregation was markedly potentiated in the presence of 10 /tM EG626. Finally, effects of adenosine in combi nation with EG626 on the cyclic AMP levels in platelets were examined. Cyclic AMP in the platelets was slightly increased by adenosine, in a concentration -dependent manner. Net increased amounts of cyclic AMP brought about by 1, 3 and 10 /iM adenosine were calculated to be 2.56, 4.54 and 6.45 pmoles/10=' platelets, respectively. EG626 in a concentration of 10 /iM did not affect the basal level (Fig. 11-A) . However, in concentrations of 30 to 300 /tM, the agent produced a concentration-dependent increase in cyclic AMP levels in platelets (data not shown). When adenosine (1, 3 and 10 uM) was used in combination with 10 /cM EG626, cyclic AMP levels in platelets were significantly increased. Net increased amounts of cyclic AMP that occurred with 1, 3 and 10 /iM adenosine in the presence of 10 /iM EG626 were approx. 3.7, 4.0 and 5.1 times those in the corresponding concen trations of adenosine without EG626 ( Fig.   1 1 -A) . It seemed likely that adenosine and EG626 had a synergistic effect in increasing cyclic AMP levels in platelets since EG626 at a concentration which did not affect cyclic AMP levels produced a significant poten tiation of the adenosine effect. Similarly, the adenosine-elicited accumulation of cyclic AMP in platelets was significantly potentiated in the presence of 30 ,oM IBMX, except for that at a concentration of 1 /eM adenosine ( Fig. 1 1 -B) . Discussion the incorporation of adenosine into platelets. Nevertheless, the antiaggregating activity and accumulation of cyclic AMP with a low concentration of adenosine were unaffected by 6TG. Moreover, 6TG did not increase cyclic AMP levels or affect platelet ag gregation.
Thus, it can be concluded that incorporation of adenosine into platelets is not required for an inhibition of aggregation or an increase in cyclic AMP to occur and that the site of action of adenosine is probably at an extracellular site(s). We speculate that potentiation of the antiaggregating activity of adenosine by papaverine or pyrimidopyri midines might be related to a mechanism(s) other than the inhibition of adenosine transport by these agents. Huang and Daly (26) reported that 6TG and other inhibitors of adenosine transport into brain slices increased the cyclic AMP response of the slices to adenosine. These authors suggested that the drugs increased the effective concen tration of adenosine at extracellular sites. The difference between the effects of 6TG in platelets and brain slices have been explained by the absence of a diffusion barrier limiting access of adenosine to the cell membrane in the former (10).
The use of an inhibitor of adenosine deaminase often appears to cause a sufficient accumulation of adenosine to trigger a biological response (27) . In our present experiments, however, a sufficiently high concentration of 2'DCF, an irreversible and potent inhibitor of adenosine deaminase (16, 28) , had no effect on the antiaggregating activity and the cyclic AMP increasing activity with adenosine.
In addition, 2'DCF neither increased cyclic AMP levels in the platelets nor affected the aggregation. Thus, the synergistic potentiation of the anti aggregating activity of adenosine by EG626 probably did not result from an inhibition of adenosine transport and/or adenosine deaminase. This speculation is supported in part by the finding that EG626 also potentiates the antiaggregating activity of 2-chloro adenosine which is not a substrate for uptake (17, 18) and adenosine deaminase (19) .
With a concomitant application, adenosine and EG626 proved to be synergistic in inhibitng platelet aggregation, according to Gaddum's method (15) . In addition, it seemed likely that adenosine and EG626 were also synergistic in increasing cyclic AMP levels in platelets since EG626 alone at a concentration not affecting cyclic AMP levels produced a significant potentiation of the increasing effect of adenosine. Therefore, one might expect that these agents are affecting different loci. There are reports indicating that EG626 is a specific inhibitor of cyclic AMP phosphodiesterase (2, 3) and that adenosine in low concentrations activates platelet adenylate cyclase (10, 11, 20 
